XRTX

XORTX Therapeutics Inc. XRTX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$92.8K total
CITADEL ADVISORS LLC
$52.5KNew
StoneX Group Inc.
$37.9KNew
ROYAL BANK OF CANADA
$2.0KNew
NATIONAL BANK OF CANADA /FI/
$329New
Clearstead Advisors, LLC
$120-80.1%
TD Waterhouse Canada Inc.
$19-80.9%
See all 6 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2021
EDGAR

ROIC

FY 2021
EDGAR

Loading ratio trend…

About XORTX Therapeutics Inc. (XRTX): stock profile, AI score and financials

XORTX Therapeutics Inc. (XRTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. XRTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of XRTX by reported 13-F value include CITADEL ADVISORS, StoneX Group, ROYAL BANK OF CANADA, based on the most recent SEC filings. XRTX trades on the Nasdaq exchange and files with the SEC under CIK 1729214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XRTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XORTX Therapeutics Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1729214 →